ONCOLOGY: SURGICAL ABLATION DEVICES MARKET

170 Pages | 56 Exhibits | 2018 Analysis | Forecasts Through 2022

OVERVIEW:
This report includes a discussion of surgical ablation devices used in oncology, emerging technologies, competitors, trends, and in-depth market analysis. Market analysis includes: 5-year market forecasts by region and ablation segment, market drivers/limiters, market share by segment and region, and trends.

ONCOLOGY MARKET HIGHLIGHTS

  • The global Surgical Ablation Devices Market for Oncology applications was valued at nearly $380m in 2017 and is expected to grow at a CAGR of more than 10% over the next 5 years.
  • The market covers 6 core ablation segments: cryoablation, high-intensity ultrasound/HIFU, irreversible electroporation/IRE, laser interstitial thermotherapy (LiTT), microwave ablation (MWA) and radiofrequency ablation (RFA)
  • In 2017, MWA was the largest segment, followed by RFA. However, HIFU, IRE and LiTT are the fastest growing segments over the forecast period (2017-2022).
  • The US market contributed the largest share of the overall ablation market in 2017, at more than 40% followed by the 5EU region at nearly 25%.
Key Questions Answered
  • What is the value of the global surgical ablation devices market for cancer applications? What is the expected growth over the next 5 years?
  • What is the market growth by major region of the world (US, 5EU, Japan, and RoW)? What is the expected growth of each ablation market segment?
  • What are the key drivers & limiters?
  • Technological trends?
  • Who are the leading competitors & estimated market share by segment & region?


TABLE OF CONTENTS:
Executive Summary

i. Cancer overview
ii. Devices market
	a. Market drivers and limiters
	b. Device segment highlights - MW ablation leads but newer technologies fuel growth
	c. Technology trends - new ablation technologies set to make cancer breakthroughs in next five years
	d. Market leaders - Medtronic leads, but competition is fierce 
	e. Competitive strategies - specific cancer indications could give the edge
	f. Emerging competition - Asian manufacturers break into market
iii. Methodology
iv. Bibliography 

Exhibit ES-1 Cancer ablation devices, global market forecast ($m), 2017-22 
Exhibit ES-2: Cancer ablation devices market, estimated sales ($m) by country/region, 2017 
Exhibit ES-3: Drivers and limiters of growth - cancer ablation devices

1. Overview of Selected Cancers and Treatment
 
1.1 Brain cancer 
	1.1.1 Treatment options
1.2 Breast cancer 
	1.2.1 Treatment options
1.3 Colorectal cancer 
	1.3.1 Treatment options
1.4 Kidney cancer
	1.4.1 Treatment options
1.5 Liver cancer
	1.5.1 Treatment options
1.6 Lung cancer
	1.6.1 Treatment options
1.7 Pancreatic cancer
	1.7.1 Treatment options
1.8 Prostate Cancer
	1.8.1 Treatment options
1.9 Bibliography 

2. Ablation Therapy Technologies

2.1 Cryoablation
	2.1.1 Kidney cancer
	2.1.2 Liver cancer
	2.1.3 Lung cancer
	2.1.4 Prostate cancer
	2.1.5 Breast cancer 
2.2 Selected cryoablation products
	2.2.1 CSA Medical 
	2.2.2 Galil Medical/BTG plc
	2.2.3 Endocare/HealthTronics
	2.2.4 IceCure Medical 
	2.2.5 Sanarus Technologies 
2.3 High-intensity focused ultrasound (HIFU)
	2.3.1 Focal HIFU
	2.3.2 FDA approval of HIFU
	2.3.3 Survey of urologists/HIFU use
2.4 Selected HIFU products
	2.4.1 Chongqing Haifu Medical Technology Co. Ltd 
	2.4.2 EDAP TMS
	2.4.3 Profound Medical 
	2.4.4 SonaCare Medical 
	2.4.5 Emerging technologies
2.5 Laser interstitial thermal therapy (LiTT) 
	2.5.1 Brain cancer 
	2.5.2 Breast cancer 
	2.5.3 Prostate cancer
2.6 Selected LITT products
	2.6.1 Medtronic 
	2.6.2 Monteris Medical
	2.6.3 Novian Health 
	2.6.4 Emerging technologies
2.7 Microwave ablation 
	2.7.1 Kidney cancer
	2.7.2 Liver cancer
	2.7.3 Lung cancer
	2.7.4 Other applications
2.8 Selected MWA products
	2.8.1 Alfresa Pharma Corp
	2.8.2 AngioDynamics 
	2.8.3 Biomedical srl
	2.8.4 ECO Medical
	2.8.5 Ethicon 
	2.8.6 HS Hospital Service SpA 
	2.8.7 Kang-Yu Medical 
	2.8.8 Medtronic 
	2.8.9 MedWaves
	2.8.10 Perseon/MedLink
	2.8.11 Emerging technologies
2.9 Radiofrequency ablation
	2.9.1 Liver tumors
	2.9.2 Lung tumors
	2.9.3 Kidney tumors
	2.9.4 Pancreatic cancer
2.10 Selected RFA products
	2.10.1 AngioDynamics 
	2.10.2 Boston Scientific
	2.10.3 HS Hospital Service SpA 
	2.10.4 Olympus Medical 
	2.10.5 Medtronic 
	2.10.6 RF Medical
	2.10.7 STARmed (Korea)
	2.10.8 Emerging technologies
2.11 Non-thermal ablation 
	2.11.1 Irreversible electroporation (IRE) 
	2.11.2 Liver cancer
	2.11.3 Pancreatic cancer
	2.11.4 Prostate cancer
2.12 Other emerging technologies
2.13 Bibliography 

Exhibit 2-1: Advantages/disadvantages of cryoablation 
Exhibit 2-2: Advantages/disadvantages of cryotherapy for kidney cancer 
Exhibit 2-3: Advantages/disadvantages of cryotherapy for liver cancer
Exhibit 2-4: Advantages/disadvantages of cryotherapy for lung cancer
Exhibit 2-5: Advantages/disadvantages of cryotherapy for prostate cancer 
Exhibit 2-6: Advantages/disadvantages of cryotherapy for breast cancer
Exhibit 2-7: Selected commercially-available cryoablation products
Exhibit 2-8: HIFU for prostate cancer via the transrectal approach 
Exhibit 2-9: Advantages/disadvantages of HIFU for prostate cancer
Exhibit 2-10: Advantages/disadvantages of LiTT for brain cancer
Exhibit 2-11: Advantages/disadvantages of LITT for breast cancer
Exhibit 2-12: MWA vs RFA ablation zone control and technique 
Exhibit 2-13: Advantages/disadvantages of MWA 
Exhibit 2-14: Advantages/disadvantages of MWA for kidney cancer
Exhibit 2-15: Advantages/disadvantages of MWA for liver cancer 
Exhibit 2-16: Advantages/disadvantages of MWA for lung cancer 
Exhibit 2-17: Selected commercially available MWA systems
Exhibit 2-18: Advantages/disadvantages of RFA 
Exhibit 2-19: Advantages/disadvantages of RFA for liver cancer
Exhibit 2-20: Advantages/disadvantages of RFA for lung cancer 
Exhibit 2-21: Advantages/disadvantages of RFA for kidney cancer
Exhibit 2-22: Advantages/disadvantages of RFA for pancreatic cancer
Exhibit 2-23: Selected RFA products
Exhibit 2-24: Advantages/disadvantages of IRE

3. Oncology: Surgical Ablation Devices Market

3.1 Market forecast: global
3.2 Market forecast: combined, by country/region 
3.3 The US market
	3.3.1 Market forecast: cryoablation 
	3.3.2 Market forecast: high-intensity focused ultrasound (HIFU)
	3.3.3 Market forecast: irreversible electroporation (IRE) 
	3.3.4 Market forecast: laser interstitial thermotherapy (LiTT)
	3.3.5 Market forecast: microwave ablation (MWA)
	3.3.6 Market forecast: radiofrequency ablation (RFA)
	3.3.7 Procedure volumes forecast: US
	3.3.8 Reimbursement: US 
3.4 The five major EU markets (5EU)
	3.4.1 Market forecast: cryoablation 
	3.4.2 Market forecast: HIFU
	3.4.3 Market forecast: IRE 
	3.4.4 Market forecast: LiTT
	3.4.5 Market forecast: MWA 
	3.4.6 Market forecast: RFA 
	3.4.7 Procedure volumes forecast: 5EU
3.5 The market in Japan
	3.5.1 Market forecast: cryoablation 
	3.5.2 Market forecast: HIFU
	3.5.3 Market forecast: IRE 
	3.5.4 Market forecast: LiTT
	3.5.5 Market forecast: MWA 
	3.5.6 Market forecast: RFA 
	3.5.7 Procedure volumes forecast: Japan
3.6 The RoW market 
	3.6.1 Market forecast: cryoablation 
	3.6.2 Market forecast: HIFU
	3.6.3 Market forecast: IRE 
	3.6.4 Market forecast: LiTT
	3.6.5 Market forecast: MWA 
	3.6.6 Market forecast: RFA 
3.7 Market drivers
3.8 Market limiters
3.9 Technology trends 
	3.9.1 Image-guided technologies and precise control
	3.9.2 RFA vs MWA
	3.9.3 HIFU emerges as the dominant treatment for prostate cancer
	3.9.4 Cryoablation set to make its mark in breast cancer
	3.9.5 LiTT's application in brain cancer is still investigational 
	3.9.6 IRE seeks clinical utility in pancreatic cancer
3.10 Global competitors: market share
3.11 Competitive analysis: cryoablation
	3.11.1 Global market share
	3.11.2 US market share
	3.11.3 5EU market share 
	3.11.4 Japan market share
	3.11.5 RoW market share 
3.12 Competitive analysis: HIFU 
	3.12.1 Global market share
	3.12.2 US market share
	3.12.3 5EU market share 
	3.12.4 Japan market share
	3.12.5 RoW market share 
3.13 Competitive analysis: IRE 
3.14 Competitive analysis: LiTT
3.15 Competitive analysis: MWA
	3.15.1 Global market share
	3.15.2 US market share
	3.15.3 5EU market share 
	3.15.4 Japan market share
	3.15.5 RoW market share 
3.16 Competitive analysis: RFA
	3.16.1 Global market share
	3.16.2 US market share
	3.16.3 5EU market share 
	3.16.4 Japan market share
	3.16.5 RoW market share 
3.17 Competitive strategies
	3.17.1 Specific approvals for cancer treatment
	3.17.2 Investment in new technology 
	3.17.3 Acquisition of ablation technologies 
	3.17.4 Overhaul of product mix
3.18 Emerging competition
	3.18.1 Competition from Asia
	3.18.2 Disruptive technology
3.19 Bibliography 
3.20 Appendix 
	3.20.1 Prostate cancer ablation survey
 
Exhibit 3-1: Cancer ablation devices, global market forecast ($m), 2017-22
Exhibit 3-2: Cancer ablation devices market, estimated sales ($m) by country/region, 2017
Exhibit 3-3: Cancer ablation devices market, estimated sales ($m) by country/region, 2017
Exhibit 3-4: US cancer ablation devices market forecast ($m), by product segment, 2017-22 
Exhibit 3-5: US cancer ablation, procedure volumes forecast, 2017-22
Exhibit 3-6: 5EU cancer ablation devices market forecast ($m), by product segment, 2017-22
Exhibit 3-7: 5EU cancer ablation, procedure volumes forecast (000s), 2017-22 
Exhibit 3-8: Japan cancer ablation devices market forecast ($m), by product segment, 2017-22
Exhibit 3-9: Japan cancer ablation, procedure volumes forecast (000s), 2017-22
Exhibit 3-10: RoW cancer ablation devices market forecast ($m), by product segment, 2017-22
Exhibit 3-11: Global cancer cryoablation devices market, share by supplier, 2017 
Exhibit 3-12: US cancer cryoablation devices market, share by supplier, 2017 
Exhibit 3-13: 5EU cancer cryoablation devices market, share by supplier, 2017
Exhibit 3-14: Japan cancer cryoablation devices market, share by supplier, 2017 
Exhibit 3-15: RoW cancer cryoablation devices market, share by supplier, 2017
Exhibit 3-16: Global cancer HIFU devices market, share by supplier, 2017 
Exhibit 3-17: US cancer HIFU devices market, share by supplier, 2017 
Exhibit 3-18: 5EU cancer HIFU devices market, share by supplier, 2017 
Exhibit 3-19: Japan cancer HIFU devices market, share by supplier, 2017
Exhibit 3-20: Global cancer microwave ablation devices market, share by supplier, 2017 
Exhibit 3-21: US cancer MW ablation devices market, share by supplier, 2017 
Exhibit 3-22: 5EU cancer MW ablation devices market, share by supplier, 2017 
Exhibit 3-23: Japan cancer MW ablation devices market, share by supplier, 2017 
Exhibit 3-24: RoW cancer MW ablation devices market, share by supplier, 2017
Exhibit 3-25: Global cancer radiofrequency ablation devices market, share by supplier, 2017 
Exhibit 3-26: US cancer RF ablation devices market, share by supplier, 2017 
Exhibit 3-27: 5EU cancer RF ablation devices market, share by supplier, 2017 
Exhibit 3-28: Japan cancer RF ablation devices market, share by supplier, 2017 
Exhibit 3-29: RoW cancer RF ablation devices market, share by supplier, 2017

Appendix A: company listing



COMPANIES COVERED:

  1. Alfresa Pharma Corporation
  2. AngioDynamics
  3. Boston Scientific
  4. Biomedical srl
  5. BTG plc
  6. Chongqing Haifu Medical Technology Co. Ltd
  7. CSA Medical
  8. ECO Medical
  9. EDAP TMS, Inc.
  10. Endocare, Inc.
  11. Erbe Elektromedizin GmbH, Inc.
  12. Ethicon, Inc.
  13. Galil Medical
  14. HealthTronics, Inc.
  15. HS Hospital Service SpA
  16. IceCure Medical
  17. Johnson & Johnson, Inc.
  18. Medtronic plc
  19. Medwaves, Inc.
  20. Metrum Cyroflex
  21. Monteris Medical
  22. NxThera, Inc.
  23. Novian Health, Inc.
  24. Olympus
  25. Perseon Medical
  26. Profound Medical Corp.
  27. RF Medical
  28. Sanarus Technologies
  29. SonaCare Medical
  30. STARmed
  31. Uptake Medical Technology
Contact Us

Need help finding medtech research? Let us help you!